CLOs on the Move

Merus

www.merus.nl

 
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.merus.nl
  • 1 Broadway
    Cambridge, MA USA 02142
  • Phone: 781.760.0013

Executives

Name Title Contact Details
Peter Silverman
Executive Vice President and General Counsel Profile

Similar Companies

AustarPharma

AustarPharma, LLC is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Fagron US

Fagron NV is a publicly traded multinational group of companies governed by Belgian law.

EMSAR

You can depend on us. Our mission is to provide quality equipment services and repairs to our valued customers across the U.S. and Canada.

Neurogastrx

We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.

CSL Behring

Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want. For a century, CSL Behring has earned a reputation as a passionate yet responsible organization, driven to care for patients and deliver on its commitments.